Skip to main
INKT
INKT logo

MiNK Therapeutics (INKT) Stock Forecast & Price Target

MiNK Therapeutics (INKT) Analyst Ratings

Based on 4 analyst ratings
Buy
Strong Buy 25%
Buy 50%
Hold 25%
Sell 0%
Strong Sell 0%

Bulls say

MiNK Therapeutics is demonstrating promising early data indicating improvements in pro-inflammatory markers, suggesting potential therapeutic responses in subsequent treatment cycles. The company's development of CAR-iNKT therapies shows promise for treating solid tumors, with an enhanced safety profile and dual immune response capabilities. Additionally, strategic moves, such as engaging in externally funded investigator-sponsored trials, position MiNK therapeutics to evaluate new indications while preserving its capital, supporting a positive long-term outlook for the company.

Bears say

MiNK Therapeutics Inc. faces several fundamental risks that contribute to a negative outlook, including potential safety signals emerging from its clinical programs, which could derail ongoing research efforts. Furthermore, the company is anticipated to require approximately $55 million in additional financing to sustain operations into mid-2025, indicating potential liquidity concerns as it navigates its development pipeline. Lastly, the recent operating loss of $2.5 million and an EPS of -$0.62 highlight ongoing financial challenges that may impact investor confidence and the company's ability to secure future funding.

MiNK Therapeutics (INKT) has been analyzed by 4 analysts, with a consensus rating of Buy. 25% of analysts recommend a Strong Buy, 50% recommend Buy, 25% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of MiNK Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About MiNK Therapeutics (INKT) Forecast

Analysts have given MiNK Therapeutics (INKT) a Buy based on their latest research and market trends.

According to 4 analysts, MiNK Therapeutics (INKT) has a Buy consensus rating as of Jul 26, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $13, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $13, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

MiNK Therapeutics (INKT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.